Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Sören Lehmann"'
Autor:
Corey Nislow, Sören Lehmann, Alex Murison, Gary D. Bader, Mark Gower, Liran I. Shlush, Benjamin Haibe-Kains, Nergiz Dogan-Artun, Rose Hurren, John E. Dick, Veronique Voisin, Cynthia J. Guidos, Sisira Kadambat Nair, Seyed Ali Madani Tonekaboni, Mathieu Lupien, Emily Heath, Mark D. Minden, Aaron D. Schimmer, Laura García-Prat, Arvind Singh Mer, Mattias Rantalainen
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Nature Communications
Nature Communications
In acute myeloid leukemia (AML), molecular heterogeneity across patients constitutes a major challenge for prognosis and therapy. AML with NPM1 mutation is a distinct genetic entity in the revised World Health Organization classification. However, di
Autor:
Åsa Rangert Derolf, Marianne Rissler, Petar Antunovic, Sören Lehmann, Lars Möllgård, Bertil Uggla, Henrik Lilljebjörn, Jörg Cammenga, Christina Orsmark-Pietras, Vladimir Lazarevic, Lovisa Wennström, Martin Höglund, Stefan Deneberg, Thoas Fioretos, Niklas Landberg, Fryderyk Lorenz
Publikováno v:
Genes, Chromosomes and Cancer. 60:426-433
Acute myeloid leukemia (AML) with t(9;22)(q34;q11), also known as AML with BCR-ABL1, is a rare, provisional entity in the WHO 2016 classification and is considered a high-risk disease according to the European LeukemiaNet 2017 risk stratification. We
Autor:
Sören Lehmann, Huthayfa Mujahed, Stefan Deneberg, Sofia Bengtzen, Anne Neddermeyer, Christer Nilsson, Sophia Miliara, Andreas Lennartsson, Karl Ekwall, Lina Cordeddu
Publikováno v:
Blood. 136:339-352
CCTC-binding factor (CTCF) is a key regulator of gene expression through organization of the chromatin structure. Still, it is unclear how CTCF binding is perturbed in leukemia or in cancer in general. We studied CTCF binding by chromatin immunopreci
Autor:
Stefan Deneberg, Vladimir Lazarevic, Lovisa Wennström, Petar Antunovic, Martin Jädersten, Martin Höglund, Sören Lehmann, Fryderyk Lorenz, Jörg Cammenga, Emma Ölander, Lars Möllgård, Gunnar Juliusson
Publikováno v:
Blood Advances. 4:1094-1101
In acute myeloid leukemia (AML) FLT3 internal tandem duplication (ITD) and nucleophosmin 1 (NPM1) mutations provide prognostic information with clinical relevance through choice of treatment, but the effect of age and sex on these molecular markers h
Autor:
Lars Möllgård, Erik Hulegårdh, Gunnar Juliusson, Dick Stockelberg, Ulla Frödin, Martin Höglund, Anders Wahlin, Stig Lenhoff, Sören Lehmann, Mats Brune, Mats Remberger, Hege Garelius, Christer Nilsson
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:1770-1778
Secondary AML (s-AML), including AML with an antecedent hematologic disorder (AHD-AML) and therapy-related AML (t-AML), constitutes a large proportion of patients with AML and is considered to confer a dismal prognosis. The role of allogeneic hematop
Publikováno v:
Haematologica. 105:249-251
Hypo, Hyper, or Combo : new paradigm for treatment of acute myeloid leukemia in older people
Autor:
Loannis Siavelis, Santeri Kiviluoto, Rozbeh Jafari, Janne Lehtiö, Lukas M. Orre, Albin Österroos, Sören Lehmann, Mattias Vesterlund, Yudi Pawitan, Wenjiang Deng, Olli Kallioniemi, Tian Mou, Brinton Seashore-Ludlow, Helena Bäckvall, Tom Erkers, Trung Nghia Vu, Anna Bohlin, Matthias Stahl, Päivi Östling
Publikováno v:
American journal of hematologyREFERENCES. 96(5)
Molecular classification of acute myeloid leukemia (AML) aids prognostic stratification and clinical management. Our aim in this study is to identify transcriptome-wide mRNAs that are specific to each of the molecular subtypes of AML. We analyzed RNA
Autor:
Martin Jädersten, Fryderyk Lorenz, Hege Garelius, Elisabeth Ejerblad, Marie Engvall, Matilda Kjellander, Ellen Backlund, Bengt Rasmussen, Lennart Nilsson, Johanna Ungerstedt, Eva Hellström-Lindberg, Sören Lehmann, Daniel Moreno Berggren
Outcomes in chronic myelomonocytic leukaemia (CMML) are highly variable and may be affected by comorbidity. Therefore, prognostic models and comorbidity indices are important tools to estimate survival and to guide clinicians in individualising treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f09845e5444f9a7596d4e858e250469
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-421139
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-421139
Autor:
Jörg Cammenga, Sören Lehmann, Lars Möllgård, Vladimir Lazarevic, Lovisa Wennström, Åsa Rangert Derolf, Martin Jädersten, Gunnar Juliusson, Mats Ehinger, Aldana Rosso, Petar Antunovic, Stefan Deneberg, Emma Ölander, Fryderyk Lorenz, Martin Höglund, Linda Fogelstrand
The Swedish national guidelines for treatment of acute myeloid leukemia (AML) recommend analysis of measurable residual disease (MRD) by multiparameter flow cytometry (MFC) in bone marrow in the routine clinical setting. The Swedish AML registry cont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f215a1543eb51ba3e644a6274c2568ce
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-454485
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-454485
Autor:
Jörg Cammenga, Albin Österroos, Emma Ölander, Anna Eriksson, Fryderyk Lorenz, Stefan Deneberg, Vladimir Lazarevic, Lovisa Wennström, Petar Antunovic, Gunnar Juliusson, Sören Lehmann, Lars Möllgård, Bertil Uggla, Åsa Derolf, Martin Höglund
Publikováno v:
British Journal of Haematology. 189
Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged >= 60 years